Loading
companiesCompany
EQT Life Sciences
The life sciences venture arm of the Swedish investment group EQT, formerly the Amsterdam firm LSP (Life Sciences Partners). It funds European and US biotech and medtech companies, including in cancer.
Overview
EQT Life Sciences calls itself 'One of Europe's Largest and Most Experienced Life Sciences Investors' with an 'Investment range 10-60M EUR', '65+' portfolio companies and '30+' investment advisory professionals, offering strategic, clinical, operational, financial and commercial support alongside capital. EQT AB, founded in Sweden in 1994, acquired Life Sciences Partners (LSP), a European venture firm, in 2021 (Wikipedia). The page cites 'unmet medical need' in conditions 'including cancer' and an insight piece titled 'How Can Investors Help to Cure Cancer?', but the featured companies shown (Amolyt Pharma, Neuravi, NewAmsterdam Pharma, Onera Health, PanTera) are not oncology companies, so no oncology portfolio example is cited here.
Portfolio (1)
Filter the startups table| Company | Stage | Type | Cancers | Latest round |
|---|---|---|---|---|
| Cyted Health Cambridge, GB | Startup | diagnostics | Oesophageal cancer | Series B 2025, $44M |
Notes
top- Amsterdam follows the task hint and LSP's historical base; the fetched page does not state an office. The full portfolio list is on a separate client-rendered page and was not readable.